fbpx
  • Home
  • Study Details
Open

Randomized, double-blind, phase III clinical trial of neoadjuvant chemotherapy or a placebo in patients with triple-negative breast cancer followed by adjubant chemotherapy or a placebo

To determine if the usual chemotherapy given before surgery for breast cancer plus an experimental drug is better than the usual chemotherapy plus a placebo.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female

Location

North Carolina (Edgecombe, Nash)

What will be asked of you

Screening, Clinic visits , Imaging

In-person visits : 50 +
Total length of participation : 9 years

Looking for Specific Volunteers

Able to participate:

  • Diagnosed with invasive adenocarcinoma of the breast

Not eligible if:

  • Definitive clinical or radiologic evidence of metastatic disease
  • Previous history of contralateral or ipsilateral invasive breast cancer
  • History of non-breast malignancies
  • Cardiac disease that would prevent the use of the study drugs

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Jayadev Manikkam umakanthan
UNC Hospitals - Nash

Study Topics

Aging
Cancer (Breast)
Surgery and post-operative healing
Women's Health
Men's Health

IRB Number

19-1760

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.